Drug intelligence / Profile preview

amlodipine besylate + benazepril hydrochloride

Development stage
Approved
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral
01

Overview

Amlodipine besylate + benazepril hydrochloride is a fixed-dose combination oral medication used to treat high blood pressure (hypertension). It combines two antihypertensive agents with complementary mechanisms of action. Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in vasodilation and reduced blood pressure. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, leading to vasodilation and decreased aldosterone-mediated water retention. The combination provides additive antihypertensive effects by targeting different pathways involved in blood pressure regulation[1][3][6]. The primary indication for this drug is the management of hypertension to reduce the risk of cardiovascular events such as stroke or heart attack[1][2][8].

Brand names
LotrelAmlobenz
Other names
amlodipine and benazeprilamlodipine and benazepril hydrochloride
02

Targets

ACE (Angiotensin Converting Enzyme)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on amlodipine besylate + benazepril hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine besylate + benazepril hydrochloride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call